Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our France register with Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer as lead sponsor. Synced 17 Nov 2026
20Current trials
17Recruiting now
1Drug in these trials
1Trial register
At a glance

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer is the lead sponsor of 20 current clinical trials in our France register. 17 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Repotrectinib. The most-studied condition is Moral Injury.

ClinicalTrials.gov trials by status

  • Recruiting1785%
  • Not yet open315%

Trials by phase

  • Not applicable1260%
  • Observational735%
  • Phase 215%
01

Clinical trials sponsored by Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

20 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Effect of Post-suction Recruitment on Lung Volume in Mechanically Ventilated ICU Patients
NCT07358039 · ClinicalTrials.gov ↗ · Mechanical Ventilation
Not applicable Recruiting 2026-04 France
Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL
NCT06893965 · ClinicalTrials.gov ↗ · Macular Diseases
Not applicable Recruiting 2025-07 France
Evaluation of a Collaborative Mental Health Care System
NCT06581874 · ClinicalTrials.gov ↗ · Psychiatric Adults Patients
Not applicable Recruiting 2025-03 France
Evaluation of the Reliability of AAR as an Independent Tool for Surgical Indication in Nasal Obstruction
NCT07379775 · ClinicalTrials.gov ↗ · Nasal Obstruction
Observational Recruiting 2026-01 France
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
NCT06552234 · ClinicalTrials.gov ↗ · NSCLC Stage IV, NSCLC, Stage III
Phase 2 Recruiting 2024-10 France
Prevalence of Obstructive Sleep Apnea in Patients With Peripheral Arterial Occlusive Disease
NCT07283289 · ClinicalTrials.gov ↗ · Peripheral Artery Disease
Observational Recruiting 2025-11 France
3D Printers for Autonomy in the Care of Inpatients in Continuing and Rehabilitation Care
NCT07087574 · ClinicalTrials.gov ↗ · Neuro-Degenerative Disease
Not applicable Recruiting 2026-03 France
Tourniquet vs. Dual-flow Arthroscopy Sheath in Anterior Cruciate Ligament (ACL) Reconstruction
NCT06819696 · ClinicalTrials.gov ↗ · Anterior Cruciate Ligament Reconstruction
Not applicable Recruiting 2025-05 France
Young Girls' Experiences of Exposure to Pornography: A Qualitative Study
NCT07812662 · ClinicalTrials.gov ↗ · Exposure to Pornography
Observational Recruiting 2025-04 France
Efficacy of Therapy With PRP Injections Versus HA in Patients With Advanced Grade of GONArthrosis
NCT07016672 · Knee Osteoarthritis
Not applicable Recruiting 2025-09 France
DVT Burden and the Risk of Post-thrombotic Syndrome
NCT06385353 · ClinicalTrials.gov ↗ · Postthrombotic Syndrome
Not applicable Recruiting 2024-06 France
Evaluation of the Care Pathway Offered by the "Chronic Disease Unit" to Obese Patients
NCT06538220 · ClinicalTrials.gov ↗ · Obesity
Not applicable Recruiting 2024-10 France
Eccentric or Concentric Contralateral Training in Rehabilitation After Shoulder Surgery With Elbow Immobilization
NCT06905093 · ClinicalTrials.gov ↗ · Shoulder Surgery
Not applicable Recruiting 2025-12 France
Moral Injury in French Healthcare Workers
NCT06926296 · ClinicalTrials.gov ↗ · Moral Injury
Not applicable Recruiting 2025-11 France
Reference Values for Knee Rotational Amplitudes in a Population of Athletes
NCT07013019 · ClinicalTrials.gov ↗ · Knee Ligament Injury
Observational Recruiting 2025-06 France
Neuroprotective Effect of Remote Ischemic Post-conditioning in Out-of-hospital Cardiac Arrest
NCT06473207 · ClinicalTrials.gov ↗ · Out-Of-Hospital Cardiac Arrest
Not applicable Recruiting 2025-01 France
Injury Incidence, Severity and Burden in Elite Youth Rugby Players
NCT07355582 · ClinicalTrials.gov ↗ · Rugby-related Injuries
Observational Recruiting 2025-12 France
Moral Injury Study Among Healthcare Professionals in Psychiatric Facilities in the PACA Region
NCT07631741 · ClinicalTrials.gov ↗ · Moral Injury
Observational Not yet open 2026-07 France
Monitoring of Patient Physiological Parameters in Real Life Using OXYFLEX® Biosensors Versus Standard Monitoring
NCT07037784 · ClinicalTrials.gov ↗ · Physiological Parameters
Not applicable Not yet open 2026-07 France
Outcome of Patients With Severe Mental Illness in the Intensive Care Unit
NCT07705802 · ClinicalTrials.gov ↗ · Severe Mental Illness, Severe Mental Disorder
Observational Not yet open 2026-09 France

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer trials

21 conditions
Moral Injury2Mechanical Ventilation1Macular Diseases1Psychiatric Adults Patients1Nasal Obstruction1NSCLC Stage IV1NSCLC, Stage III1Peripheral Artery Disease1Neuro-Degenerative Disease1Anterior Cruciate Ligament Reconstruction1Exposure to Pornography1Knee Osteoarthritis1Postthrombotic Syndrome1Physiological Parameters1Obesity1Shoulder Surgery1Knee Ligament Injury1Severe Mental Illness1Severe Mental Disorder1Out-Of-Hospital Cardiac Arrest1Rugby-related Injuries1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in France2017

A trial with sites in more than one country appears in each of those registers.

05

Questions about Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer trials

How many clinical trials does Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer sponsor?

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer is the lead sponsor of 20 current trials on ClinicalTrials.gov in our France register, as of the registry sync on 17 November 2026. Completed and withdrawn studies are not counted.

Are Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer trials recruiting?

Yes. 17 of its 20 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Repotrectinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 17 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.